Peter Snyder is a tenured professor of biomedical and pharmaceutical sciences at the University of Rhode Island. Additionally, he serves as the consulting chief medical officer and as a member of the Scientific Advisory Board for MindImmune, Inc. He is the founding editor-in-chief for Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, an open access journal of the Alzheimer’s Association. Dr. Snyder manages a robust research program, he publishes regularly within this field, and he has delivered over 200 presentations at international scientific conferences. His academic interests span across a range of topics in neuropharmacology, neurophysiology, history of neuroscience, and research ethics. His clinical interests are currently focused on the topics of aging and dementia. From 1998 through 2005, Dr. Snyder served as a scientist, clinician and director at Pfizer Global Research & Development. As an early clinical leader at Pfizer, he led the development of novel compounds for the treatment of schizophrenia and Alzheimer’s disease. Dr. Snyder has continued to consult to a wide range of pharmaceutical companies since he left Pfizer in 2005. Dr. Snyder is a Fellow of the American Psychological Association (Div. 40, Clinical Neuropsychology; Div. 6, Behavioural Neuroscience). He has published two texts that focus on the management of scientific integrity and research ethics within academic medical centers.